The Formulary Management Expert Committee (FMEC) recommends that ibrutinib in combination with immunochemotherapy with or without autologous stem cell transplant (ASCT) be reimbursed for previously untreated, transplant-eligible patients with mantle cell lymphoma (MCL), provided certain conditions are met.
